28 completed, 8 unknown, 1 not yet recruiting. 27 Phase 1, 5 Phase 3, 4 Phase 4, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 27 | Completed 23, Unknown 4 |
| Phase 3 | 5 | Completed 3, Unknown 2 |
| Phase 4 | 4 | Unknown 2, Completed 1, Not yet recruiting 1 |
| Phase 2 | 1 | Completed 1 |
Follow lobeglitazone: new trials by email Literature Review of lobeglitazone trials Research Report on lobeglitazone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.25/12.5/1000mg in Healthy Volunteers CKD-383 0.25/12.5/1000mg, CKD-501, D745, D150 - Type 2 Diabetes | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 30 | 2025-10-30 | 2025-12-26 |
| Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/10/1000mg in Healthy Volunteers CKD-383 0.5/10/1000mg, CKD-501, D744, D150 - Type 2 Diabetes | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 30 | 2025-10-28 | 2025-12-26 |
| Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/25/1000mg in Healthy Volunteers CKD-383 0.5/25/1000mg, CKD-501, D745, D150 - Type 2 Diabetes | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 31 | 2025-10-24 | 2025-12-26 |
| Effect of Add-on SGLT2i, TZD, or Combination Therapy in Type 2 Diabetes Patients on DPP4 Inhibitors Sitagliptin 100 mg, Sitagliptin 100 mg + Dapagliflozin 10 mg, Sitagliptin 100 mg + Dapagliflozin 10 mg + Lobeglitazone 0.5 mg - Diabetes Mellitus, Type 2, Hyperglycemia | Phase 4 | Not yet recruiting | Yonsei University | 100 | 2025-09-01 | 2025-08-07 |
| To Evaluate the Food Effect on Pharmacokinetic Profiles and Safety in Healthy Volunteers CKD-383(Fed), CKD-383(Fasted) - Type 2 Diabetes Mellitus | Phase 1 | Unknown | Chong Kun Dang Pharmaceutical | 28 | 2024-07-04 | 2024-07-10 |
| Evaluate the Pharmacokinetics and Safety Between the Treatment of CKD-383 and Treatment of CKD-501, D745, D150, and D029 CKD-383, CKD-501, D745, D150, D029 - Type 2 Diabetes | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 30 | 2023-07-14 | 2024-01-23 |
| Evaluate the Pharmacokinetics and Safety Between the Administration of CKD-383 and the Co-administration of CKD-501, D744, and D150 CKD-383, CKD-501, D744, D150 - Type 2 Diabetes | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 32 | 2023-05-26 | 2024-01-23 |
| A Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393(2) in Healthy Volunteers Under Fed Conditions CKD-393(2), CKD-501, D759, D150, D029 - Type2Diabetes | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 31 | 2022-04-21 | 2022-06-30 |
| Comparison of Dapagliflozin, Lobeglitazone, and Its Combination in Efficacy and Safety Dapagliflozin 10mg Tab, Lobeglitazone 0.5 mg, Dapagliflozin + Lobeglitazone - Diabetes Type 2 | Phase 4 | Unknown | Seoul National University Bundang Hospital | 99 | 2022-01-01 | 2023-08-14 |
| Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393 CKD-393, CKD-501, D759, H053 - Type 2 Diabetes | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 33 | 2021-11-25 | 2023-06-09 |
| Evaluate the Drug-drugs Interaction Between Lobeglitazone 0.5mg and Empagliflozin 25mg CKD-398, CKD-501, D745 - Type 2 Diabetes Mellitus | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 32 | 2021-05-27 | 2021-08-25 |
| A Clinical Trial to Evaluate the Pharmacokinetic Profiles and Safety of CKD-383. CKD-501, D745, D150, CKD-383 - Type2 Diabetes Mellitus | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 27 | 2021-04-16 | 2021-06-10 |
| Clinical Trial to Investigate the Pharmacokinetics and Safety of CKD-393 CKD-501, D759, D150, CKD-393 0.5/100/1000 mg - T2DM (Type 2 Diabetes Mellitus) | Phase 1 | Unknown | Chong Kun Dang Pharmaceutical | 26 | 2021-02-18 | 2021-01-12 |
| A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D759 and D150 (CKD-393) CKD 501, D759, D150, CKD-501, D759, D150 - Type 2 Diabetes Mellitus | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 48 | 2020-06-15 | 2020-11-16 |
| A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D745 and D150 CKD-501, D745, D150, CKD-501, D745, D150 - Type 2 Diabetes | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 48 | 2020-05-07 | 2020-10-30 |
| Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-393 in Healthy Subjects CKD-501 0.5mg Tab. 1T, D759 100mg Tab. 1T and D150 1000mg Tab. 1T, CKD-393 0.5/100/1000mg formulation 1 Tab. 1T, CKD-393 0.5/100/1000mg formulation 2 Tab. 1T - Diabetes Mellitus, Type 2 | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 24 | 2020-04-08 | 2021-04-30 |
| A Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-396 CKD-501 and D759, CKD-396 - Type2 Diabetes Mellitus | Phase 1 | Unknown | Chong Kun Dang Pharmaceutical | 26 | 2020-02-24 | 2020-02-05 |
| Clinical Trial to Evaluate the Drug Drug Interaction of CKD-501 and D308 D308, CKD-501 - Diabetes Mellitus, Type II | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 41 | 2018-07-25 | 2018-11-19 |
| The Efficacy and Safety of CKD-501 Added to D150 Plus D759 Therapy in Patients With Type 2 Diabetes CKD-501 0.5mg, Placebo - Type2 Diabetes | Phase 3 | Unknown | Chong Kun Dang Pharmaceutical | 240 | 2018-05-02 | 2018-08-22 |
| Efficacy and Safety of CKD-501 Added to D150 Plus D745 25mg Therapy in Patients With Type 2 Diabetes CKD-501 0.5mg, Placebo - Type2 Diabetes | Phase 3 | Unknown | Chong Kun Dang Pharmaceutical | 240 | 2018-04-26 | 2018-08-13 |
Showing 20 of 37. Sign in to see all of them.
Diabetes Mellitus, Type 2 (26) · Hyperglycemia (1) · Insulin Resistance (1) · Liver Diseases (1) · Renal Insufficiency (1)
Chong Kun Dang Pharmaceutical (33) · Seoul National University Bundang Hospital (3) · Yonsei University (1)
South Korea (34)
Anhye Kim, Ph.D (3) · BongSoo Cha, Ph.D (2) · Ji Young Park, Ph.D. (2) · Min Gul Kim, M.D, Ph.D. (2) · Min Soo Park, Ph.D. M.D (2) · Min-Gul Kim, MD,PhD (2) · Minsoo Park (2) · Choon Ok Kim, M.D., Ph.D. (1) · Choon Ok Kim, M.D., PhD. (1) · Dongseop Choi (1) · Dongseop Choi, MD.,Ph.D. (1) · Jae Kuk Shin, Ph.D. M.D (1) · Jae Wook Ko, Ph.D (1)
PMID 32362346, PMID 22697273, PMID 24736628, PMID 25047497, PMID 26163202, PMID 31992459, PMID 33099742, PMID 33953542, PMID 37034122